Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Prayers on their way to your nephew, his family, and you.
Sorry....my previous post was meant for Longfellow95
Coincidentally, and because the Royal Marsden was named in your post, I just came across the following article this morning - perhaps you have already read it:
https://www.firstwordpharma.com/node/1543697?tsid=28®ion_id=4
Are the recent (2.13.2018) 13G SEC documents filed by NW in preparation for a Shareholder vote?
https://www.sec.gov/cgi-bin/browse-edgar?company=Northwest+Biotherapeutics&owner=exclude&action=getcompany
The issue of shorting, manipulation, etc. involved with NWBO stock has been a part of this MB for the six years I have been monitoring my investment. Although this article is not connected to NWBO, it is an interesting read and has been the subject of CNBC throughout the day:
Cognate BioServices continues to post new job opportunities:
CAPA/Deviation Coordinator
On February 6, 2018
Technical Writer – Quality Control
On February 6, 2018
Director, QC Microbiology
On February 6, 2018
Holy fruit salad Batman, I’ve been reading the NWBO message board since 2012 - day after day; week after week - year after year - trying to keep up with the shenanigans and here it is all wrapped up in one comprehensive paragraph.
I didn’t see any speaking placements for NWBO; however, UCLA (Dr. Antoni Ribas) is quite prominent at this symposium.
It does appear that we are maintaining a presence where we need to be until publication or a “go” for data release.
I join my fellow posters in thanking you for your efforts in putting together the ASM “minutes.” I’m sure I am not alone in forwarding content rich posts to my circle of NWBO investors.
Evaluate….
Thanks for the concise post - Note one of your mentions:
This may have been posted previously:
2018 ASCO
NWBO
Booth 10161 60 x 20
Booth 13152 60 x 60
http://events.jspargo.com/ASCO18/Public/eventmap.aspx?ID=66135&shmode=E&sortMenu=102001
Good morning Eagle….
If you don’t have this proxy statement info from the NWBO website, here it is:
https://www.nwbio.com/Proxy-Statement-January-09-2018.pdf
Marzan, your comments are appropriately enthusiastic.
NWBO will have an exhibit at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco January 25-28, 2018. I do not see an NWBO speaker
at this time.
http://events.jspargo.com/immuno18/Public/exhibitors.aspx?ID=68668&sortMenu=102002#
Fair enough
As a point of interest re the Jan conference: NWBO was only listed as a sponsor within the past two weeks or so. Cognate and TrakCel have been listed for quite some time. This statement falls within the limitations of my search only and is not a statement of fact.
After the speakers’ presentation, the agenda offers a “Q&A and Meet and Greet with the Speakers” time. Since NWBO is in a silence cone, I imagine their presence there - at this time - is to highlight their visibility and to signal their coming status in the industry.
I did not find a presentation by NWBO; however, the CEO of Cognate is presiding over a roundtable discussion on Tuesday, Jan. 23rd. There are a number of “reserved presentation” listed on the agenda.
Thanks Gus
Roche and Ignyta reach definitive merger agreement
https://www.roche.com/investors/updates/inv-update-2017-12-22.htm
Ditto...
Avastin-Tecentriq combo announcement
https://www.firstwordpharma.com/node/1529020?tsid=28®ion_id=6
Hey, good morning, Marzan
Good post. I am with you in belief that DCVax is the golden ticket.
Additional news on Roche's Tecentriq, Avastin, chemotherapy combination
https://www.firstwordpharma.com/node/1528022?tsid=28®ion_id=6
FDA Grants Genentech’s Avastin full approval from provisional approval:
https://www.firstwordpharma.com/node/1527774?tsid=28®ion_id=3
What do we know about payer influence on NWBO approval and their part in bringing DCVax to commercialization? Should NWBO products become the SOC for certain treatments, will other therapies/drugs that have received FDA approval face loss of coverage or an adjustment to coverage?
…..”Now payers are demanding evidence of drug safety and effectiveness that goes far beyond what the FDA requires for market approval as a basis for prescription drug coverage.”
https://www.statnews.com/2017/02/28/fda-payers-new-therapies/
Could some of the silence be attributed to payer negotiations?
At your leisure, you may enjoy reading an interview with NW - Financial Times UK
https://www.msn.com/en-gb/money/news/neil-woodford-will-investors-keep-the-faith/ar-BBFZubK?li=BBoPWjQ